Chai Discovery will route select biotechs through Lilly TuneLab, offering Frontier AI model capabilities for drug discovery

Chai Discovery said it has partnered with Eli Lilly to make certain Chai Discovery “frontier” AI model capabilities available to selected biotechnology companies through Lilly’s TuneLab initiative. The announcement, published June 18, positions the companies as pushing more of their AI-enabled drug-discovery workflows into external partner settings rather than limiting them to internal use.

Chai Discovery, described in the announcement as an AI company focused on engineering models to discover new molecules, did not specify in the published note how the AI capability would be packaged for biotechs. It said only that “certain” capabilities from its frontier AI model suite would be made available to companies that are part of the program.

Eli Lilly’s TuneLab is referenced as the mechanism for delivery in the partnership. The announcement frames TuneLab as the pathway connecting Chai Discovery’s AI capabilities with participating biotechs, suggesting TuneLab is intended to support research collaborations and enable access to specialized tooling in a structured way.

The parties did not disclose which specific model functions would be provided, the nature of the deliverables biotechs would receive, or whether access would be limited to specific therapeutic areas, stages of discovery, or proprietary data inputs. The announcement also does not name participating biotechs or list any contract terms such as funding levels, duration, or exclusivity.

For Chai Discovery, the deal is another announcement of how AI-native drug discovery is moving toward partner ecosystems. AI model developers increasingly look to biotechs for early adoption because smaller companies may be more willing to test new computational approaches, particularly when the output can be translated into laboratory programs.

For Eli Lilly, the announcement fits a broader strategy of building external-facing discovery infrastructure. By connecting a third-party AI model developer’s capabilities to TuneLab, Lilly can expand the range of computational options available to partners without having to rely solely on internal model development timelines.

The collaboration’s near-term impact on revenue and pipeline timelines is unclear from the June 18 notice. Without disclosure of partner identities, milestone structure, or performance metrics, investors and researchers will not be able to directly measure the commercial or scientific outcomes of the effort from the announcement alone.

What to watch next is whether Lilly or Chai Discovery releases additional details, such as the types of model capabilities being shared, how biotechs will evaluate outputs, and any publicly listed partner companies. The market will likely focus on whether the program is described as progressing beyond pilots into broader deployments, and whether follow-on announcements tie the collaboration to measurable discovery milestones.